You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: January 2022 to February 2026

AbstractFullPdf
Jan 202210410924
Feb 202214361466607
Mar 2022427440270
Apr 2022375398191
May 2022365382154
Jun 2022471498150
Jul 202238339294
Aug 2022486497159
Sep 2022460470118
Oct 202211331169235
Nov 2022746755191
Dec 2022413420143
Jan 2023478485135
Feb 2023510516170
Mar 2023413421127
Apr 2023381387114
May 202335336298
Jun 202333333979
Jul 202326827486
Aug 202346346974
Sep 202338739468
Oct 202351251692
Nov 202378278689
Dec 2023373375163
Jan 2024146147200
Feb 202437137281
Mar 2024368371108
Apr 202429129263
May 202424324550
Jun 202423423459
Jul 202418819073
Aug 202413313649
Sep 202414314656
Oct 202421521861
Nov 202424224576
Dec 202421121990
Jan 202517217860
Feb 202534835287
Mar 202523523576
Apr 202521421563
May 202513313584
Jun 202511011042
Jul 2025110
Sep 2025110
Feb 2026110
Total16052163635009